October 18, 2024 10:29 AM EDT
R&D
Pharma

Pfiz­er ends tri­al of Ar­ray-ac­quired SHP2 in­hibitor af­ter sim­i­lar cuts from peers

Kyle LaHucik

Senior Reporter

Pfiz­er has end­ed its tri­al of an SHP2 in­hibitor that was be­ing de­vel­oped in can­cer, the lat­est blow to the tar­get af­ter sev­er­al oth­er drug­mak­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

A con­ver­sa­tion with No­bel Prize win­ner David Bak­er on the fu­ture of AI in pro­tein de­sign — and be­yond

Ex­clu­sive: Ex-Af­fimed CEO heads to UK nanomed­i­cine biotech; Ja­mi Ru­bin leaves Bound­less Bio af­ter IPO

Gilead pulls Trodelvy's ac­cel­er­at­ed la­bel in blad­der can­cer af­ter drug failed con­fir­ma­to­ry study

Pfiz­er’s RSV vac­cine has 90% ef­fi­ca­cy against se­vere res­pi­ra­to­ry dis­ease

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times